[HTML][HTML] Drug repurposing approach to fight COVID-19
Currently, there are no treatment options available for the deadly contagious disease,
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
[HTML][HTML] SARS-CoV-2: an emerging coronavirus that causes a global threat
J Zheng - International journal of biological sciences, 2020 - ncbi.nlm.nih.gov
An ongoing outbreak of pneumonia caused by a novel coronavirus, currently designated as
the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was reported recently …
the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was reported recently …
[HTML][HTML] Antiviral drug discovery: preparing for the next pandemic
Clinically approved antiviral drugs are currently available for only 10 of the more than 220
viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need …
viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need …
Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID‐19
JS Khalili, H Zhu, NSA Mak, Y Yan… - Journal of medical …, 2020 - Wiley Online Library
Confronting the challenge of the outbreak of COVID‐19 should sharpen our focus on global
drug access as a key issue in antiviral therapy testing. The testing and adoption of effective …
drug access as a key issue in antiviral therapy testing. The testing and adoption of effective …
Synthesis and characterization of gelatin/lignin hydrogels as quick release drug carriers for Ribavirin
In this study, hydrogels based on gelatin and lignin were fabricated as efficient drug carriers
for Ribavirin. The obtained hydrogels were characterized by scanning electron microscopy …
for Ribavirin. The obtained hydrogels were characterized by scanning electron microscopy …
[HTML][HTML] SARS and MERS: recent insights into emerging coronaviruses
E De Wit, N Van Doremalen, D Falzarano… - Nature reviews …, 2016 - nature.com
Abstract The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in
2012 marked the second introduction of a highly pathogenic coronavirus into the human …
2012 marked the second introduction of a highly pathogenic coronavirus into the human …
[HTML][HTML] Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
The COVID-19 pandemic progresses unabated in many regions of the world. An effective
antiviral against SARS-CoV-2 that could be administered orally for use following high-risk …
antiviral against SARS-CoV-2 that could be administered orally for use following high-risk …
RNA-dependent RNA polymerase as a target for COVID-19 drug discovery
W Zhu, CZ Chen, K Gorshkov, M Xu… - … the Science of Drug …, 2020 - journals.sagepub.com
COVID-19 respiratory disease caused by the severe acute respiratory syndrome coronavirus-
2 (SARS-CoV-2) has rapidly become a global health issue since it emerged in December …
2 (SARS-CoV-2) has rapidly become a global health issue since it emerged in December …
[HTML][HTML] Broad-spectrum antiviral strategies and nucleoside analogues
RJ Geraghty, MT Aliota, LF Bonnac - Viruses, 2021 - mdpi.com
The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such
as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory …
as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory …
[HTML][HTML] Antivirals for COVID-19: a critical review
No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as
the development of antivirals usually requires time. Therefore, assessment and use of …
the development of antivirals usually requires time. Therefore, assessment and use of …